Dr Reddy's Laboratories Ltd ADR
RDY: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$75.00 | Xrkht | Qrcmcqpzt |
Dr. Reddy's Posts Solid Results After Strong Season of Product Launches
Dr. Reddy’s posted solid second-quarter results. A confluence of factors led to strong top line growth, but we place this in perspective against the high costs of maintaining market share in this industry long-term. We maintain our fair value estimate of $49 per share and our no-moat rating.